Evidence map›Paper›PMID 41653266›Full record

Observational studyEuropean journal of nuclear medicine and molecular imaging2026

Prognostic parameters and detection of cardiac amyloidosis with hybrid

Lukas Kessler, Wibke Tonscheidt, Kai Nassenstein, Stephan Settelmeier, Alexander Carpinteiro, H Christian Reinhardt, Tim Hagenacker, Lale Umutlu, Christoph Kleinschnitz, Simon Wernhart and 11 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Lukas KesslerDepartment of Nuclear Medicine, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany. lukas.kessler@uk-essen.de.ORCID 0000-0003-1751-8837
Wibke TonscheidtDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, 45147 , Essen, Germany.
Kai NassensteinDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Stephan SettelmeierDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, 45147 , Essen, Germany.
Alexander CarpinteiroDepartment of Hematology, West German Tumor Center, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
H Christian ReinhardtDepartment of Hematology, West German Tumor Center, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Tim HagenackerDepartment of Neurology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Lale UmutluDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Christoph KleinschnitzDepartment of Neurology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Simon WernhartDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, 45147 , Essen, Germany.
Lars MichelDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, 45147 , Essen, Germany.
Michal K ChodylaDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Benedikt M SchaarschmidtDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Thomas-Wilfried SchlosserDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Wolfgang P FendlerDepartment of Nuclear Medicine, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Francesco BarbatoDepartment of Nuclear Medicine, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Maria PapathanasiouDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, 45147 , Essen, Germany.
Christoph RischplerDepartment of Nuclear Medicine, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Ken HerrmannDepartment of Nuclear Medicine, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Tienush RassafDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, 45147 , Essen, Germany.
David KerstingDepartment of Nuclear Medicine, University Hospital Essen, Hufelandstrasse 55, 45147, Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePositron emission tomography (PET) with amyloid-binding tracers was shown to have high sensitivity for the detection of both transthyretin (ATTR) and light-chain (AL) cardiac amyloidosis (CA). Recent studies describe prognostic value of imaging biomarkers from bone scintigraphy and

methodsPatients who underwent cardiac

resultsTwenty-one patients with confirmed CA were enrolled. MACEs were reported in 14 of 21 patients (66.7%). Higher average RI was the only imaging biomarker that was a significant predictor for MACE in uni- and multivariate analysis (HR = 4.02, 95%CI: 1.25-12.9, p < 0.05). N-terminal pro-B-type natriuretic peptide (NT-proBNP) was a significant predictor in uni- but not in multivariate analysis. Patients with AL-CA showed a higher rate of MACE than patients with other subtypes.

conclusionIntegrated

Indexed as

AmyloidosisAniline CompoundsMagnetic Resonance ImagingMultimodal ImagingPositron-Emission TomographyStilbenesAgedAged, 80 and overBiomarkersFemaleHumansMaleMiddle AgedPrognosis4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbeneAniline CompoundsBiomarkersStilbenesAmyloid-binding tracersCardiac amyloidosisLight-chainMolecular imagingPositron emission tomographyTransthyretin

Identifiers

PMID41653266
PMCPMC13121523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.